Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from a Phase II study presented for the first time at the American Headache Society (AHS) annual meeting showed that MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved migraine pain relief two hours after dosing compared to placebo, and the relief was sustained through 24 hours. MK-0974 was generally well tolerated in the study. Responses specific to other measures, such as migraine-associated symptoms, functional disability and use of additional rescue medications also were reported. MK-0974 is Merck's investigational medicine in Phase III clinical development for the acute treatment of migraine in adults and, if approved, may be the first in a new class of migraine treatments since the approval of the first triptan drug in 1991.

"The findings of this early-stage trial demonstrate the therapeutic potential of MK-0974 for the acute treatment of migraines," said Tony Ho, M.D., senior director of Clinical Neuroscience, Merck Research Laboratories. "Larger clinical trials, such as those now underway, will provide more insight into the efficacy and safety profile of MK-0974."

About MK-0974

MK-0974 is an antagonist of the receptor for CGRP, a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses. MK-0974 blocks the binding of CGRP to receptors within these areas and thereby is believed to inhibit the transmission of pain signals that lead to migraine headaches.

Study design

The findings being presented are from a randomized, double-blind, placebo- and active-controlled dose-ranging clinical trial in patients wi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:8/30/2015)... 31, 2015 Noser Health ... to deliver new platform ... citizen-owned health data transaction platform, announced today strategic partnerships ... to engineer and bring to market its global health ... "Our business model is built on trust, ...
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Bevacizumab ... Developed by Roche under the trade name of Avastin, ... world. In Feb.26, 2010, it was approved by CFDA ... in China all come from ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:8/31/2015)... ... ... MeYou Health ®, a social well-being company and wholly owned subsidiary ... including an in-app step tracker. , Walkadoo is a pedometer-based walking program ... broadly assign every Walkadoo member 10,000 steps a day (as is typical for many ...
(Date:8/31/2015)... ... 31, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announces the agenda and open ... the Hyatt Regency Reston in Reston, Va. from October 26-29, WEDI-Con will convene ...
(Date:8/31/2015)... , ... August 31, 2015 , ... It’s a lot ... executive director of GreenFields of Geneva. During his first days on the job, he’s ... been nice seeing them, and I like knowing that they’re living in such a ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... firm, introduces the Talent Management Division , a department devoted to helping ... sales department. Talent management goes beyond selection, and The Brooks Group believes in ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Organization Supporting Business Owners and provided a tour of their North American facility ... success possible to international companies expanding business in the U.S. , The ...
Breaking Medicine News(10 mins):Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:PartnerTech Supports Economic Growth as Host 2
... ... , ... July 8, 2010 -- GENCO Supply Chain Solutions, North America’s second largest and a ... and Regulatory Affairs, GENCO Pharmaceutical Services, spoke on June 30 before the U.S. Senate ...
... A surgery developed at Hospital for Special Surgery can ... foot deformity, a problem that is increasingly being seen ... surgery have better long-term outcome and mobility than those ... at the annual meeting of the American Orthopaedic Foot ...
... ... Clothing4all continues to impress consumers all over the globe with their unbeatable embroidery and ... successful year. , ... Eugene, Oregon (PRWEB) July 8, 2010 -- Uncle Sam can’t hold down this ...
... ... availability of the EV30T, a new addition to its powerful line of ... the United States. The U.S. Department of Health and Human Services reports ... care spending, decreased productivity and increased safety risks. Lifeloc is proud to ...
... ... has achieved the Project Management Professional (PMP) credential with the Project Management Institute ... ... announce that Aaron Alsop has achieved the Project Management Professional (PMP) credential with ...
... Swanson Health Products ... ... -- The prebiotic that has been a favorite source of soluble fiber in powder form ... a unique soluble fiber that offers superior benefits for gastrointestinal health combined with excellent digestive ...
Cached Medicine News:Health News:Mary Hendrickson of GENCO Pharmaceutical Services Speaks Before Senate on the Topic of Drug Take-Back Programs 2Health News:Mary Hendrickson of GENCO Pharmaceutical Services Speaks Before Senate on the Topic of Drug Take-Back Programs 3Health News:Mary Hendrickson of GENCO Pharmaceutical Services Speaks Before Senate on the Topic of Drug Take-Back Programs 4Health News:New surgery improves outcomes for severe flat foot deformity 2Health News:New surgery improves outcomes for severe flat foot deformity 3Health News:Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales 2Health News:Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T 2Health News:Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T 3Health News:DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute 2Health News:New Form of FiberAid™ Added to Swanson Ultra 2
... were designed for ease of use, and ... blood sample is collected. The wider-diameter BD ... an integrated collection scoop and improved mixing ... is available for hematology and chemistry applications, ...
... The Identity pacemaker family, which includes ... clinicians with the most advanced pacemaker ... Suppression algorithm, the first and only ... suppress atrial fibrillation (AF). The AF ...
... The Identity pacemaker family, which includes ... clinicians with the most advanced pacemaker ... Suppression algorithm, the first and only ... suppress atrial fibrillation (AF). The AF ...
... Identity pacemaker family, which includes the ... with the most advanced pacemaker technology ... algorithm, the first and only U.S. ... atrial fibrillation (AF). The AF Suppression ...
Medicine Products: